The most frequent enzyme-related glycolytic deficit that causes red cell hemolysis is PKD (pyruvate kinase deficiency). Medical heterogeneity is a trait of this illness. Variable levels of hemolysis brought on by heterogeneity lead to irreparable cellular damage.
Hereditary non-spherocytic anemia is a constant side effect of PKD. From the neonatal era until adulthood, manifestations take place. Hemolytic anemia may lead to a variety of problems.
Epidemiology
PKD was first identified by Valentine et al. in 1961. Since this discovery, news has spread across the globe. An uncommon condition, PKD. The unknown is the true prevalence of PKD. The estimated prevalence of PKD in Western people is between 3.2 and 8.5 cases per million. A frequency of 1:20,000 has already been noted, though.
The frequency of mutant alleles may be close to 51 in million. Tunisia and Brazil have case clusters. There doesn’t seem to be much data on gender differences in PKD. In other communities, like the Romani and Amish in Pennsylvania, some mutations are more prevalent.
This observation might be explained by a few things. A founding effect shows that mutations are heritable. Specific migrant couples have been linked to certain mutations. Consanguinity also raises the likelihood of homozygosity.
Anatomy
Pathophysiology
RBC ATPases that are membrane-bound protect the cells’ integrity. ATPases swap potassium for sodium. As a result, cellular fluid equilibrium, deformability, and transcellular electrical and chemical neutrality are all preserved. RBC ATP generation is reduced by PK enzyme deficiency, which reduces RBC deformability.
Fluid loss and intracellular potassium toxicity also happen. Damage to RBC is the result. Enzyme concentrations of 25percent or lower cause PKD to emerge. Hepatic and splenic capillaries seize damaged RBCs. Hepatosplenomegaly is caused by extravascular hemolysis. Additionally, hemoglobinuria can be brought on by intravascular hemolysis.
The growing weariness in PKD is caused by anemia. Elevated 2,3-DPG results in tissue oxygen discharge. This causes the oxygen dissociation graph to shift to the right. Increased 2,3-DPG aids in anemia restitution. In patients who are homozygotic, these mechanisms are at work. The majority of heterozygote carriers exhibit no symptoms.
Hemolysis, however, can happen under stressful circumstances. A lack of folate is caused by prolonged hemolysis. Extramedullary hemopoiesis has been documented in PKD. RBCs in newborns use more ATP than adult RBCs. Exchange transfusion may be necessary to avoid kernicterus because the splenic loss of reticulocytes results in hyperbilirubinemia.
Fetal hydrops can be the consequence of extreme anemia in pregnancy. Newborn anemia that requires transfusions may happen. These people get dilutional anemia throughout the second trimester of pregnancy. RBC mass rises more slowly than plasma levels.
It seems likely that maternal hemodilution leads to better fetal results. Additionally, it reduces postpartum loss of blood. PKD may make a pregnant woman’s physiological anemia worse. Periodic hemolysis may call for RBC replacement by transfusion.
Etiology
Glycolysis is crucial to the metabolism of red blood cells (RBCs). The enzyme pyruvate kinase (PK) is essential to this procedure. Phosphoenolpyruvate is changed into pyruvate by PK. This process results in 50 percent of Erythrocyte ATP. For the purpose of reducing methemoglobin, PK controls NADH synthesis.
These metabolites are necessary for RBCs to function properly. Cell energy efficiencies and lifespan are reduced in PKD. In PKD, young RBCs are particularly impacted. The PK-LR gene controls the expression of PK. The gene is found on 1q21 of the chromosome. The inheritance pattern for PKD is autosomal recessive.
Both compound heterozygotes and homozygotes are impacted. Two distinct mutant genotypes are inherited by complex heterozygotes. There have been discovered about 300 mutations that cause PKD. Most of these mutations are missense ones. However, reports of new mutations have been made. Mutations of the frameshift, deletion and insertion types can happen.
Genetics
Prognostic Factors
In PKD, the prognosis is quite unpredictable. Early intervention and severity of disease affect results. In especially during pregnancy, hemosiderosis and serious anemia are risky and undesirable.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
https://www.ncbi.nlm.nih.gov/books/NBK560581/
News
Vaping’s ‘95% Safer’ Claim Debated for Youth Health
Posted on
News
Google DeepMind’s AI Revolutionizes the Search for Disease Genes
Posted on
News
Mosquitoes Pose New Challenge to Public Health
Posted on
News
3D-Printed e3-skin Redefines Wearable Health Monitoring
The most frequent enzyme-related glycolytic deficit that causes red cell hemolysis is PKD (pyruvate kinase deficiency). Medical heterogeneity is a trait of this illness. Variable levels of hemolysis brought on by heterogeneity lead to irreparable cellular damage.
Hereditary non-spherocytic anemia is a constant side effect of PKD. From the neonatal era until adulthood, manifestations take place. Hemolytic anemia may lead to a variety of problems.
PKD was first identified by Valentine et al. in 1961. Since this discovery, news has spread across the globe. An uncommon condition, PKD. The unknown is the true prevalence of PKD. The estimated prevalence of PKD in Western people is between 3.2 and 8.5 cases per million. A frequency of 1:20,000 has already been noted, though.
The frequency of mutant alleles may be close to 51 in million. Tunisia and Brazil have case clusters. There doesn’t seem to be much data on gender differences in PKD. In other communities, like the Romani and Amish in Pennsylvania, some mutations are more prevalent.
This observation might be explained by a few things. A founding effect shows that mutations are heritable. Specific migrant couples have been linked to certain mutations. Consanguinity also raises the likelihood of homozygosity.
RBC ATPases that are membrane-bound protect the cells’ integrity. ATPases swap potassium for sodium. As a result, cellular fluid equilibrium, deformability, and transcellular electrical and chemical neutrality are all preserved. RBC ATP generation is reduced by PK enzyme deficiency, which reduces RBC deformability.
Fluid loss and intracellular potassium toxicity also happen. Damage to RBC is the result. Enzyme concentrations of 25percent or lower cause PKD to emerge. Hepatic and splenic capillaries seize damaged RBCs. Hepatosplenomegaly is caused by extravascular hemolysis. Additionally, hemoglobinuria can be brought on by intravascular hemolysis.
The growing weariness in PKD is caused by anemia. Elevated 2,3-DPG results in tissue oxygen discharge. This causes the oxygen dissociation graph to shift to the right. Increased 2,3-DPG aids in anemia restitution. In patients who are homozygotic, these mechanisms are at work. The majority of heterozygote carriers exhibit no symptoms.
Hemolysis, however, can happen under stressful circumstances. A lack of folate is caused by prolonged hemolysis. Extramedullary hemopoiesis has been documented in PKD. RBCs in newborns use more ATP than adult RBCs. Exchange transfusion may be necessary to avoid kernicterus because the splenic loss of reticulocytes results in hyperbilirubinemia.
Fetal hydrops can be the consequence of extreme anemia in pregnancy. Newborn anemia that requires transfusions may happen. These people get dilutional anemia throughout the second trimester of pregnancy. RBC mass rises more slowly than plasma levels.
It seems likely that maternal hemodilution leads to better fetal results. Additionally, it reduces postpartum loss of blood. PKD may make a pregnant woman’s physiological anemia worse. Periodic hemolysis may call for RBC replacement by transfusion.
Glycolysis is crucial to the metabolism of red blood cells (RBCs). The enzyme pyruvate kinase (PK) is essential to this procedure. Phosphoenolpyruvate is changed into pyruvate by PK. This process results in 50 percent of Erythrocyte ATP. For the purpose of reducing methemoglobin, PK controls NADH synthesis.
These metabolites are necessary for RBCs to function properly. Cell energy efficiencies and lifespan are reduced in PKD. In PKD, young RBCs are particularly impacted. The PK-LR gene controls the expression of PK. The gene is found on 1q21 of the chromosome. The inheritance pattern for PKD is autosomal recessive.
Both compound heterozygotes and homozygotes are impacted. Two distinct mutant genotypes are inherited by complex heterozygotes. There have been discovered about 300 mutations that cause PKD. Most of these mutations are missense ones. However, reports of new mutations have been made. Mutations of the frameshift, deletion and insertion types can happen.
In PKD, the prognosis is quite unpredictable. Early intervention and severity of disease affect results. In especially during pregnancy, hemosiderosis and serious anemia are risky and undesirable.
https://www.ncbi.nlm.nih.gov/books/NBK560581/
medtigo
Pyruvate Kinase Deficiency
Updated :
September 5, 2023
The most frequent enzyme-related glycolytic deficit that causes red cell hemolysis is PKD (pyruvate kinase deficiency). Medical heterogeneity is a trait of this illness. Variable levels of hemolysis brought on by heterogeneity lead to irreparable cellular damage.
Hereditary non-spherocytic anemia is a constant side effect of PKD. From the neonatal era until adulthood, manifestations take place. Hemolytic anemia may lead to a variety of problems.
PKD was first identified by Valentine et al. in 1961. Since this discovery, news has spread across the globe. An uncommon condition, PKD. The unknown is the true prevalence of PKD. The estimated prevalence of PKD in Western people is between 3.2 and 8.5 cases per million. A frequency of 1:20,000 has already been noted, though.
The frequency of mutant alleles may be close to 51 in million. Tunisia and Brazil have case clusters. There doesn’t seem to be much data on gender differences in PKD. In other communities, like the Romani and Amish in Pennsylvania, some mutations are more prevalent.
This observation might be explained by a few things. A founding effect shows that mutations are heritable. Specific migrant couples have been linked to certain mutations. Consanguinity also raises the likelihood of homozygosity.
RBC ATPases that are membrane-bound protect the cells’ integrity. ATPases swap potassium for sodium. As a result, cellular fluid equilibrium, deformability, and transcellular electrical and chemical neutrality are all preserved. RBC ATP generation is reduced by PK enzyme deficiency, which reduces RBC deformability.
Fluid loss and intracellular potassium toxicity also happen. Damage to RBC is the result. Enzyme concentrations of 25percent or lower cause PKD to emerge. Hepatic and splenic capillaries seize damaged RBCs. Hepatosplenomegaly is caused by extravascular hemolysis. Additionally, hemoglobinuria can be brought on by intravascular hemolysis.
The growing weariness in PKD is caused by anemia. Elevated 2,3-DPG results in tissue oxygen discharge. This causes the oxygen dissociation graph to shift to the right. Increased 2,3-DPG aids in anemia restitution. In patients who are homozygotic, these mechanisms are at work. The majority of heterozygote carriers exhibit no symptoms.
Hemolysis, however, can happen under stressful circumstances. A lack of folate is caused by prolonged hemolysis. Extramedullary hemopoiesis has been documented in PKD. RBCs in newborns use more ATP than adult RBCs. Exchange transfusion may be necessary to avoid kernicterus because the splenic loss of reticulocytes results in hyperbilirubinemia.
Fetal hydrops can be the consequence of extreme anemia in pregnancy. Newborn anemia that requires transfusions may happen. These people get dilutional anemia throughout the second trimester of pregnancy. RBC mass rises more slowly than plasma levels.
It seems likely that maternal hemodilution leads to better fetal results. Additionally, it reduces postpartum loss of blood. PKD may make a pregnant woman’s physiological anemia worse. Periodic hemolysis may call for RBC replacement by transfusion.
Glycolysis is crucial to the metabolism of red blood cells (RBCs). The enzyme pyruvate kinase (PK) is essential to this procedure. Phosphoenolpyruvate is changed into pyruvate by PK. This process results in 50 percent of Erythrocyte ATP. For the purpose of reducing methemoglobin, PK controls NADH synthesis.
These metabolites are necessary for RBCs to function properly. Cell energy efficiencies and lifespan are reduced in PKD. In PKD, young RBCs are particularly impacted. The PK-LR gene controls the expression of PK. The gene is found on 1q21 of the chromosome. The inheritance pattern for PKD is autosomal recessive.
Both compound heterozygotes and homozygotes are impacted. Two distinct mutant genotypes are inherited by complex heterozygotes. There have been discovered about 300 mutations that cause PKD. Most of these mutations are missense ones. However, reports of new mutations have been made. Mutations of the frameshift, deletion and insertion types can happen.
In PKD, the prognosis is quite unpredictable. Early intervention and severity of disease affect results. In especially during pregnancy, hemosiderosis and serious anemia are risky and undesirable.
https://www.ncbi.nlm.nih.gov/books/NBK560581/
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
